Details for Patent: 8,236,755
✉ Email this page to a colleague
Which drugs does patent 8,236,755 protect, and when does it expire?
Patent 8,236,755 protects BRIXADI and is included in one NDA.
This patent has one hundred and fifteen patent family members in thirty-three countries.
Summary for Patent: 8,236,755
| Title: | Opioid depot formulations |
| Abstract: | The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: |
| Inventor(s): | Thuresson Krister, Tiberg Fredrik, Johansson Markus, Harwigsson Ian, Joabsson Fredrik, Johnsson Markus |
| Assignee: | Camurus AB |
| Application Number: | US11798495 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 8,236,755
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-001 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF DELIVERY OF AN OPIOID BIOACTIVE AGENT. A METHOD OF TREATMENT OR PROPHYLAXIS OF A HUMAN OR NON-HUMAN ANIMAL FOR THE TREATMENT OF OPIOID ADDICTION AND/OR THE SYMPTOMS OF OPIOID WITHDRAWAL | ⤷ Sign Up | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-002 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF DELIVERY OF AN OPIOID BIOACTIVE AGENT. A METHOD OF TREATMENT OR PROPHYLAXIS OF A HUMAN OR NON-HUMAN ANIMAL FOR THE TREATMENT OF OPIOID ADDICTION AND/OR THE SYMPTOMS OF OPIOID WITHDRAWAL | ⤷ Sign Up | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-003 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF DELIVERY OF AN OPIOID BIOACTIVE AGENT. A METHOD OF TREATMENT OR PROPHYLAXIS OF A HUMAN OR NON-HUMAN ANIMAL FOR THE TREATMENT OF OPIOID ADDICTION AND/OR THE SYMPTOMS OF OPIOID WITHDRAWAL | ⤷ Sign Up | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-004 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF DELIVERY OF AN OPIOID BIOACTIVE AGENT. A METHOD OF TREATMENT OR PROPHYLAXIS OF A HUMAN OR NON-HUMAN ANIMAL FOR THE TREATMENT OF OPIOID ADDICTION AND/OR THE SYMPTOMS OF OPIOID WITHDRAWAL | ⤷ Sign Up | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-005 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF DELIVERY OF AN OPIOID BIOACTIVE AGENT. A METHOD OF TREATMENT OR PROPHYLAXIS OF A HUMAN OR NON-HUMAN ANIMAL FOR THE TREATMENT OF OPIOID ADDICTION AND/OR THE SYMPTOMS OF OPIOID WITHDRAWAL | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,236,755
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E401054 | ⤷ Sign Up | |||
| Austria | E462409 | ⤷ Sign Up | |||
| Austria | E501710 | ⤷ Sign Up | |||
| Australia | 2005249274 | ⤷ Sign Up | |||
| Australia | 2005324794 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
